

Supplementary Table S1. Information (title, authors, year of publication, type of research, country of origin) of the top 10 cited articles (ranked by their annual citation rate). BD: Behçet's disease.

TOP 10 CITED ARTICLES (ranking by annual citation rate)					
Title	Authors	Year of publication	Type of research	Country	Annual citation rate
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with BD	Remmers <i>et al.</i>	2010	Translational	Collaboration	48.10
The International Criteria for BD (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria	International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD)	2014	Clinical	Collaboration	45.00
The long-term mortality and morbidity of BD: a 2-decade outcome survey of 387 patients followed at a dedicated centre	Kural-Seyahi <i>et al.</i>	2003	Clinical	Turkey	36.47
Uveitis in BD: an analysis of 880 patients	Tugal-Tutkun <i>et al.</i>	2004	Clinical	Turkey	29.75
Effect of infliximab on sight-threatening panuveitis in BD	Sfikakis <i>et al.</i>	2001	Clinical	Greece	28.74
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in BD with refractory uveoretinitis	Ohno <i>et al.</i>	2004	Clinical	Japan	24.25
Interleukin-1 β -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of BD: an open-label pilot study	Gül <i>et al.</i>	2012	Clinical	Turkey	23.88
Upregulated IL-23 and IL-17 in BD patients with active uveitis	Chi <i>et al.</i>	2008	Translational	China	22.58
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in BD: an open-label trial.	Tugal-Tutkun <i>et al.</i>	2005	Clinical	Turkey	20.40
Short-term trial of etanercept in BD: a double blind, placebo-controlled study.	Melikoglu <i>et al.</i>	2005	Clinical	Turkey	20.07